Understanding the Market | TRANSCENTA-B is currently up over 4%, ozekibart will submit a U.S. indication marketing application before mid-next year
TRANSCENTA-B once surged nearly 10% during trading, and as of the time of publication, it rose 4.75% to HKD 3.09, with a trading volume of HKD 4.006 million. In terms of news, TRANSCENTA announced that its partner Inhibrx Biosciences, Inc. recently reported positive primary results from the registrational clinical study of the tetravalent death receptor 5 (DR5) agonistic antibody ozekibart, which evaluated the efficacy of ozekibart monotherapy compared to placebo in patients with advanced or metastatic, unresectable sarcoma. Based on these results, Inhibrx plans to submit a marketing authorization application for the sarcoma indication of this product to U.S. regulators by the end of June 2026. TRANSCENTA currently holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan
According to Zhitong Finance APP, TRANSCENTA-B (06628) rose nearly 10% during intraday trading, and as of the time of publication, it is up 4.75%, priced at HKD 3.09, with a trading volume of HKD 4.006 million.
In terms of news, TRANSCENTA announced that its partner Inhibrx Biosciences, Inc. (INBX.US) recently reported positive primary results from the registration clinical study of the four-valent death receptor 5 (DR5) agonistic antibody ozekibart, which evaluated the efficacy of ozekibart monotherapy compared to placebo in patients with advanced or metastatic, unresectable sarcoma.
Based on these results, Inhibrx plans to submit a marketing authorization application for the sarcoma indication to U.S. regulatory authorities by the end of June 2026. TRANSCENTA currently holds exclusive development and commercialization rights for ozekibart in China, Hong Kong, Macau, and Taiwan
